Total Payments
$35,732
2024 Payments
$6,236
Companies
92
Transactions
1,553
Medicare Patients
6,843
Medicare Billing
$4.5M
Payment Breakdown by Category
Food & Beverage$31,649 (88.6%)
Education$2,502 (7.0%)
Other$1,281 (3.6%)
Consulting$300.00 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $31,649 | 1,496 | 88.6% |
| Education | $2,502 | 41 | 7.0% |
| Long term medical supply or device loan | $1,281 | 14 | 3.6% |
| Consulting Fee | $300.00 | 2 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,660 | 165 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,451 | 105 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,154 | 86 | $0 (2024) |
| PFIZER INC. | $2,054 | 140 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,856 | 89 | $0 (2024) |
| Amgen Inc. | $1,788 | 74 | $0 (2024) |
| Janssen Biotech, Inc. | $1,630 | 58 | $0 (2024) |
| Incyte Corporation | $1,404 | 49 | $0 (2024) |
| Celgene Corporation | $1,378 | 78 | $0 (2024) |
| Genentech USA, Inc. | $1,377 | 75 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,236 | 222 | AstraZeneca Pharmaceuticals LP ($498.79) |
| 2023 | $5,937 | 211 | Novartis Pharmaceuticals Corporation ($492.94) |
| 2022 | $6,752 | 240 | Novartis Pharmaceuticals Corporation ($746.09) |
| 2021 | $6,324 | 225 | Novartis Pharmaceuticals Corporation ($1,191) |
| 2020 | $2,656 | 146 | Amgen Inc. ($259.19) |
| 2019 | $2,715 | 161 | Novartis Pharmaceuticals Corporation ($287.19) |
| 2018 | $2,623 | 176 | PFIZER INC. ($304.74) |
| 2017 | $2,489 | 172 | E.R. Squibb & Sons, L.L.C. ($327.58) |
All Payment Transactions
1,553 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/23/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Education | In-kind items and services | $84.99 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nubeqa | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Oncology | ||||||
| 12/16/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.40 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $124.46 | General |
| 12/12/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $26.41 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $1.07 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $4.76 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: Rare Disease | ||||||
| 12/02/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $4.67 | General |
| Category: Hematology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: Oncology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $124.46 | General |
| 11/25/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $32.46 | General |
| Category: Oncology | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.74 | General |
| 11/21/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: CELLT | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.98 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 1,569 | 60,898 | $4.1M | $984,565 |
| 2022 | 35 | 1,827 | 92,499 | $4.1M | $1.0M |
| 2021 | 36 | 1,812 | 76,591 | $5.2M | $1.3M |
| 2020 | 36 | 1,635 | 77,654 | $4.9M | $1.2M |
Total Patients
6,843
Total Services
307,642
Medicare Billing
$4.5M
Procedure Codes
141
All Medicare Procedures & Services
141 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 11,000 | $1.6M | $477,493 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 32 | 15,420 | $1.1M | $281,702 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 347 | $77,728 | $33,838 | 43.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 65 | 332 | $227,752 | $33,050 | 14.5% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 12 | 1,900 | $141,100 | $31,988 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 274 | 490 | $88,200 | $31,504 | 35.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 12 | 15,750 | $78,750 | $13,754 | 17.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 178 | $48,060 | $9,815 | 20.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 72 | 72 | $30,240 | $8,948 | 29.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 58 | 357 | $54,264 | $8,005 | 14.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 11 | 57 | $224,466 | $7,668 | 3.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 62 | 137 | $41,648 | $6,662 | 16.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 92 | $14,444 | $5,840 | 40.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 44 | $13,068 | $4,545 | 34.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 84 | $28,056 | $4,197 | 15.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 143 | 520 | $18,200 | $3,938 | 21.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 144 | $22,464 | $3,132 | 13.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 68 | 261 | $24,273 | $2,849 | 11.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 16 | 108 | $26,892 | $2,686 | 10.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 115 | 265 | $5,035 | $2,226 | 44.2% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 14 | 35 | $11,550 | $2,170 | 18.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 39 | 135 | $14,175 | $1,628 | 11.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $4,140 | $1,460 | 35.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 45 | $6,345 | $1,049 | 16.5% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 29 | 1,190 | $145,180 | $980.86 | 0.7% |
About Dr. Gregory Hoang, MD
Dr. Gregory Hoang, MD is a Hematology & Oncology healthcare provider based in Palm Bay, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952362816.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Hoang, MD has received a total of $35,732 in payments from pharmaceutical and medical device companies, with $6,236 received in 2024. These payments were reported across 1,553 transactions from 92 companies. The most common payment nature is "Food and Beverage" ($31,649).
As a Medicare-enrolled provider, Hoang has provided services to 6,843 Medicare beneficiaries, totaling 307,642 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 141 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Palm Bay, FL
- Active Since 03/30/2006
- Last Updated 05/16/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1952362816
Products in Payments
- OPDIVO (Biological) $2,033
- KEYTRUDA (Biological) $1,990
- KISQALI (Drug) $1,895
- JAKAFI (Drug) $944.20
- TAGRISSO (Drug) $756.07
- LIBTAYO (Biological) $694.60
- IMBRUVICA (Drug) $620.83
- Lenvima (Drug) $594.14
- Kyprolis (Drug) $582.40
- ADCETRIS (Biological) $538.73
- ERLEADA (Drug) $516.48
- REBLOZYL (Biological) $510.34
- IBRANCE (Drug) $477.38
- XTANDI (Drug) $465.20
- LYNPARZA (Drug) $421.44
- TECENTRIQ (Biological) $388.99
- ENHERTU (Biological) $375.28
- PROMACTA (Drug) $362.05
- RYBREVANT (Drug) $343.27
- Revlimid (Drug) $341.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.